

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

<b>Name of entity</b>	Little Green Pharma Ltd
<b>ACN</b>	615 586 215

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Michael David Lynch-Bell
<b>Date of last notice</b>	6 September 2022

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	N/A
<b>Date of change</b>	27 February 2023
<b>No. of securities held prior to change</b>	833,743 Ordinary shares 440,000 Retention Share Rights
<b>Class</b>	(a) Fully paid ordinary shares (b) Fully paid ordinary shares (c) Unlisted options, exercisable at \$0.25 each, expiring 19 July 2024 (d) Retention Share Rights
<b>Number acquired</b>	(a) 250,000 Fully paid ordinary shares (b) 300,000 Fully paid ordinary shares (c) 250,000 Unlisted options, exercisable at \$0.25 each, expiring 19 July 2024
<b>Number disposed</b>	(d) 300,000 Retention Share Rights

---

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	(a) \$0.20 per share (b) Nil consideration - conversion of incentive rights issued in connection with the February 2020 IPO and vesting after three years of service achieved on 20 February 2023 (c) Nil consideration – free attaching to Placement Shares (a) (d) Nil per (b) above
<b>No. of securities held after change</b>	1,383,743 Ordinary shares 250,000 Unlisted options, exercisable at \$0.25 each, expiring 19 July 2024 140,000 Retention Share Rights
<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Issue of securities approved at general meeting on 31 January 2023

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
<b>Interest after change</b>	

**Part 3 – +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

+ See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

<b>Name of entity</b>	Little Green Pharma Ltd
<b>ACN</b>	615 586 215

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Neale William Fong
<b>Date of last notice</b>	6 September 2022

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	Riverpalm Pty Ltd ATF NW Fong Family Trust - Dr Fong is a director and beneficiary of the trust  Dr Neale Fong ATF Damblock Trust - Dr Fong is a trustee and beneficiary of the trust
<b>Date of change</b>	27 February 2023
<b>No. of securities held prior to change</b>	Riverpalm Pty Ltd <NW Fong Family Trust> 296,154 Ordinary shares  Dr Neale Fong <Damblock Trust> 791,871 Ordinary shares 220,000 Retention Share Rights
<b>Class</b>	(a) Fully paid ordinary shares (b) Fully paid ordinary shares (c) Unlisted options, exercisable at \$0.25 each, expiring 19 July 2024 (d) Retention Share Rights

\* The previous balance reported on 12 March 2021 did not include 46,154 shares purchased through the Company's Share Purchase Plan on 11 March 2021 which was disclosed in the Share Purchase Plan Offer Booklet dated 15 February 2021.

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Number acquired</b>	(a) 125,000 Fully paid ordinary shares (b) 150,000 Fully paid ordinary shares (c) 125,000 Unlisted options, exercisable at \$0.25 each, expiring 19 July 2024
<b>Number disposed</b>	(d) 150,000 Retention Share Rights
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	(a) \$0.20 per share (b) Nil consideration - conversion of incentive rights issued in connection with the February 2020 IPO and vesting after three years of service achieved on 20 February 2023 (c) Nil consideration – free attaching to Placement Shares (a) (d) Nil per (b) above
<b>No. of securities held after change</b>	Riverpalm Pty Ltd <NW Fong Family Trust> 296,154 Ordinary shares  Dr Neale Fong <Damblock Trust> 1,066,871 Ordinary shares 70,000 Retention Share Rights 125,000 Unlisted options, exercisable at \$0.25 each, expiring 19 July 2024
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of securities approved at general meeting on 31 January 2023

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	
<b>Interest after change</b>	

**Part 3 – +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	No
----------------------------------------------------------------------------------------------------------------------------------------------------	----

\* The previous balance reported on 12 March 2021 did not include 46,154 shares purchased through the Company's Share Purchase Plan on 11 March 2021 which was disclosed in the Share Purchase Plan Offer Booklet dated 15 February 2021.

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

\* The previous balance reported on 12 March 2021 did not include 46,154 shares purchased through the Company's Share Purchase Plan on 11 March 2021 which was disclosed in the Share Purchase Plan Offer Booklet dated 15 February 2021.

---

+ See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

<b>Name of entity</b>	Little Green Pharma Ltd
<b>ACN</b>	615 586 215

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Fleta Jennifer Solomon
<b>Date of last notice</b>	6 September 2022

### Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct & indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	Fleta Solomon Super Pty Ltd as trustee for Solomon Super Fund - Ms Solomon is a director of the trustee and beneficiary
<b>Date of change</b>	27 February 2023
<b>No. of securities held prior to change</b>	<u>Direct</u> 20,273,439 Fully paid ordinary shares  333,334 Class C Performance Rights 333,333 Class D Performance Rights 333,333 Class E Performance Rights 500,000 Class F Performance Rights 500,000 Class G Performance Rights 500,000 Class H Performance Rights 72,000 Share Rights
<b>Class</b>	(a) Fully paid ordinary shares (b) Fully paid ordinary shares (c) Class I, J, K Performance rights (d) Unlisted options, exercisable at \$0.25 each, expiring 19 July 2024 (e) Class C Performance Rights (f) Class D Performance Rights (g) Class E Performance Rights

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Number acquired</b>	(a) 250,000 Fully paid ordinary shares (b) 1,000,000 Fully paid ordinary shares (c) 1,500,000 Performance rights (500,000 each Class I, J & K) (d) 250,000 Unlisted options, exercisable at \$0.25 each, expiring 19 July 2024
<b>Number disposed</b>	(e) 333,334 Class C Performance Rights (f) 333,333 Class D Performance Rights (g) 333,333 Class E Performance Rights
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	(a) \$0.20 per share (b) Nil consideration - conversion of incentive rights issued in connection with the February 2020 IPO, performance milestones achieved in December 2020 and February 2021 and vesting after two years of service (c) Nil consideration – issued to incentivise performance based on share price milestones of \$0.50, \$0.60 and \$0.75 with vesting occurring over two years of service after achieving milestones (d) Nil consideration – free attaching to Placement Shares (a) (e), (f) and (g) – Nil per (b) above
<b>No. of securities held after change</b>	<u>Direct</u> 21,273,439 fully paid ordinary shares 500,000 Class F Performance Rights 500,000 Class G Performance Rights 500,000 Class H Performance Rights 500,000 Class I Performance Rights 500,000 Class J Performance Rights 500,000 Class K Performance Rights 72,000 Share Rights  <u>Indirect</u> 250,000 fully paid ordinary shares 250,000 Unlisted options, exercisable at \$0.25 each, expiring 19 July 2024
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of securities approved at general meeting on 31 January 2023

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	
<b>Interest acquired</b>	

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>Interest disposed</b>	
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
<b>Interest after change</b>	

**Part 3 – +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

+ See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

<b>Name of entity</b>	Little Green Pharma Ltd
<b>ACN</b>	615 586 215

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Angus McDougall Caithness
<b>Date of last notice</b>	6 September 2022

### Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct & indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	<p>Banquo Consulting Pty Ltd - Mr Caithness is a director</p> <p>Angus Caithness SMSF Pty Ltd as trustee for the Caithness Superannuation Fund - Mr Caithness is a director of the trustee and beneficiary</p>
<b>Date of change</b>	27 February 2023
<b>No. of securities held prior to change</b>	<p><u>Direct</u> 1,410,942 Ordinary shares 166,667 Class C Performance Rights 166,666 Class D Performance Rights 166,667 Class E Performance Rights</p> <p><u>Indirect</u> <i>Banquo Consulting Pty Ltd</i> 9,016,000 Ordinary shares 500,000 Class F Performance Rights 500,000 Class G Performance Rights 500,000 Class H Performance Rights 64,000 Share Rights</p>

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Class</b>	(a) Fully paid ordinary shares (b) Fully paid ordinary shares (c) Class I, J, K Performance rights (d) Unlisted options, exercisable at \$0.25 each, expiring 19 July 2024 (e) Class C Performance Rights (f) Class D Performance Rights (g) Class E Performance Rights
<b>Number acquired</b>	(a) 250,000 Fully paid ordinary shares (b) 500,000 Fully paid ordinary shares (c) 1,500,000 Performance rights (500,000 each Class I, J & K) (d) 250,000 Unlisted options, exercisable at \$0.25 each, expiring 19 July 2024
<b>Number disposed</b>	(e) 166,667 Class C Performance Rights (f) 166,666 Class D Performance Rights (g) 166,667 Class E Performance Rights
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	(a) \$0.20 per share (b) Nil consideration - conversion of incentive rights issued in connection with the February 2020 IPO, performance milestones achieved in December 2020 and February 2021 and vesting after two years of service (c) Nil consideration – issued to incentivise performance based on share price milestones of \$0.50, \$0.60 and \$0.75 with vesting occurring over two years of service after achieving milestones (d) Nil consideration – free attaching to Placement Shares (a) (e), (f) and (g) – Nil per (b) above
<b>No. of securities held after change</b>	<u>Direct</u> 2,010,942 Ordinary shares 100,000 Unlisted options, exercisable at \$0.25 each, expiring 19 July 2024  <u>Indirect</u> <i>Banquo Consulting Pty Ltd</i> 9,016,000 Ordinary shares 500,000 Class F Performance Rights 500,000 Class G Performance Rights 500,000 Class H Performance Rights 500,000 Class I Performance Rights 500,000 Class J Performance Rights 500,000 Class K Performance Rights 64,000 Share Rights  <i>Angus Caithness SMSF Pty Ltd as trustee for the Caithness Superannuation Fund</i> 150,000 Ordinary shares 150,000 Unlisted options, exercisable at \$0.25 each, expiring 19 July 2024

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<p><b>Nature of change</b>          Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	<p>Issue of securities approved at general meeting on 31 January 2023</p>
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	---------------------------------------------------------------------------

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<p><b>No. and class of securities to which interest related prior to change</b>  <small>Note: Details are only required for a contract in relation to which the interest has changed</small></p>	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<p><b>Value/Consideration</b>  <small>Note: If consideration is non-cash, provide details and an estimated valuation</small></p>	
<b>Interest after change</b>	

**Part 3 – +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

+ See chapter 19 for defined terms.